Collecting Data from Pregnant Partners of Research Subjects Policy/Procedure

Internal Approval
SVP, Research
EVP & Chief Scientific Officer, Research

Scope
This policy describes the required process when a researcher or sponsor wants to obtain data from pregnant partners of research subjects. When males are enrolled in clinical studies, researchers are often interested in evaluating whether the investigational drugs, devices, and/or procedures have effects on their pregnant female partners and their fetuses. Pregnant partners who are not participants in the research should be consented for this purpose. This includes information about the pregnancy and child after birth.

Definitions
Under Department of Health and Human Services (HHS) per 45 CFR 46.102:
Research: A systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge

Human subject: A living individual about whom an investigator (whether professional or student) conducting research: (1) obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens or (2) obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimen.

Under FDA per 21 CFR 50.3:
(c) Clinical investigation: Any experiment that involves a test article and one or more human subjects and that either is subject to requirements for prior submission to the Food and Drug Administration under section 505(i) or 520(g) of the act, or is not subject to requirements for prior submission to the Food and Drug Administration under these sections of the act, but the results of which are intended to be submitted later to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit. The term does not include experiments that are subject to the provisions of part 58 of this chapter, regarding nonclinical laboratory studies.

(g) Human subject: An individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient.

(j) Test article means any drug (including a biological product for human use), medical device for human use, human food additive, color additive, electronic product, or any other article subject to regulation under the act or under sections 351 and 354-360F of the Public Health Service Act (42 U.S.C. 262 and 263b-263n).

Policy Statements

The Boston Children's Hospital Institutional Review Board (IRB) considers the pregnant partner, fetus, and child to be research subjects because the researcher is collecting identifiable private information (under HHS) and the partner, fetus, and/or child is participating in the investigation by allowing the collection of information about their (indirect) receipt of the test article (under FDA).

Special Pediatric/Adolescent Considerations

In a pediatric setting the pregnant partner may be a minor. Massachusetts statute, Chapter 112, Section 12F provides that "[a]ny minor may give consent to his medical or dental care at the time such care is sought if . . . (iv) she is pregnant or believes herself to be pregnant." The statute further provides that "[t]he consent of the parent or legal guardian shall not be required to authorize such care" and "[a]ll information and records kept in connection with the medical or dental care of a minor who consents thereto in accordance with this section shall be confidential between the minor and the physician or dentist, and shall not be released except upon the written consent of the minor or a proper judicial order."

1. Therefore, the (minor) pregnant partner may be contacted to provide consent for collection of information related to this pregnancy.

2. The parent of this partner does not need to be contacted.

Procedures

Written consent/authorization from the pregnant partner is required if data and information relating to the pregnancy will be collected from identifiable records.

1. Obtaining consent requires talking with the subject about the desire to obtain the information about the pregnant partner and the subsequent birth if applicable.

2. No information regarding the partner's pregnancy (accompanied with identifiers) should be recorded by the study team or the sponsor until the partner has given permission and signed
the consent/authorization form.

It is important to preserve the professional relationship that exists between the subject and the study team. The initial approach for permission from the partner must be via the subject (with their permission) and the Boston Children's Hospital research study team.

A consent form for the pregnant partner must include the Boston Children's Hospital HIPAA language.

1. The purpose listed on the consent/authorization should be the collection of information about the pregnant partner, fetus, and/or child, not the purpose of the research in which the male partner is participating.

2. The pregnant partner consent and HIPAA Authorization form should be submitted before any data is collected on a pregnant partner, fetus, and/or child.
   a. It may be submitted with the initial study documents or at a later date when data collection is imminent, as long as enough time is allowed for IRB review and approval before its anticipated use.

3. There needs to be the ability for a pregnant partner to "opt out" of additional data collection on their child.

4. It is also important to specify in the consent form the time period requested for continued access to records regarding the pregnancy and birth.
   a. The time should not be open ended.
   b. Children have several steps of increasing autonomy which should correspond with decisions about use of their data.
   c. Providing parental permission to access their data in infancy requires defining the time frame.
   d. If there is long term follow up, reasonable expectations might include re-consenting the family at age 10-12, so that the developing child's autonomy may be taken into consideration.

Researchers should consult with the IRB as needed for study specific issues or situations not outlined in this policy.

Related Content

- Department of Health and Human Services Regulations: HHS 45 CFR 46.102
- U.S. Food & Drug Administration: 21 CFR 50.3
- Commonwealth of Massachusetts General Laws: 112 Section 12F

Approval Signatures

<table>
<thead>
<tr>
<th>Step Description</th>
<th>Approver</th>
<th>Date</th>
</tr>
</thead>
</table>
Applicability

Boston Children's Hospital- Policies & Procedures